← Browse by Condition
Medical Condition

oligometastatic disease

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for oligometastatic disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — oligometastatic disease Clinical Trials

How many clinical trials are currently recruiting for oligometastatic disease?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for oligometastatic disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for oligometastatic disease?
oligometastatic disease research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a oligometastatic disease clinical trial?
Eligibility criteria for oligometastatic disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
European Organisation for Research and Treatment of Cancer - EORTC 1 trial
MedSIR 1 trial
University Health Network, Toronto 1 trial
Universitaire Ziekenhuizen KU Leuven 1 trial

Recruiting Clinical Trials

NCT06462963
Recruiting

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

Enrollment
302 pts
Location
Belgium, Italy, Neth...
Sponsor
European Organisation for Rese...
View Trial →
NCT06180356 Phase 2
Recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

Enrollment
30 pts
Location
Spain
Sponsor
MedSIR
View Trial →
NCT06668454
Recruiting

Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)

Enrollment
72 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT05352178 Phase 3
Recruiting

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Enrollment
873 pts
Location
Belgium
Sponsor
Universitaire Ziekenhuizen KU ...
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology